{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Steinmann SM"],"funding":["Associazione Italiana per la Ricerca sul Cancro","University of Sassari"],"pagination":["2055"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9917075"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(3)"],"pubmed_abstract":["Hepatocellular carcinoma (HCC) is a primary liver tumor with high lethality and increasing incidence worldwide. While tumor resection or liver transplantation is effective in the early stages of the disease, the therapeutic options for advanced HCC remain limited and the benefits are temporary. Thus, novel therapeutic targets and more efficacious treatments against this deadly cancer are urgently needed. Here, we investigated the pathogenetic and therapeutic role of eukaryotic initiation factor 4A1 (eIF4A1) in this tumor type. We observed consistent eIF4A1 upregulation in HCC lesions compared with non-tumorous surrounding liver tissues. In addition, <i>eIF4A1</i> levels were negatively correlated with the prognosis of HCC patients. In HCC lines, the exposure to various eIF4A inhibitors tri"],"journal":["International journal of molecular sciences"],"pubmed_title":["eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma."],"pmcid":["PMC9917075"],"funding_grant_id":["Fondo di Ateneo per la Ricerca 2019","IG19175"],"pubmed_authors":["Tanzer E","Marin JJG","Desaubry L","Sanchez-Martin A","Simile MM","Evert M","Calvisi DF","Steinmann SM","Cigliano A","Pes GM"],"additional_accession":[]},"is_claimable":false,"name":"eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.","description":"Hepatocellular carcinoma (HCC) is a primary liver tumor with high lethality and increasing incidence worldwide. While tumor resection or liver transplantation is effective in the early stages of the disease, the therapeutic options for advanced HCC remain limited and the benefits are temporary. Thus, novel therapeutic targets and more efficacious treatments against this deadly cancer are urgently needed. Here, we investigated the pathogenetic and therapeutic role of eukaryotic initiation factor 4A1 (eIF4A1) in this tumor type. We observed consistent eIF4A1 upregulation in HCC lesions compared with non-tumorous surrounding liver tissues. In addition, <i>eIF4A1</i> levels were negatively correlated with the prognosis of HCC patients. In HCC lines, the exposure to various eIF4A inhibitors tri","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-25T19:20:16.164Z","creation":"2025-04-06T07:56:29.857Z"},"accession":"S-EPMC9917075","cross_references":{"pubmed":["36768380"],"doi":["10.3390/ijms24032055"]}}